MedKoo Biosciences

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us





Back to products


 Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries


Other drug agents

Drug intermediates

Bio-reagents and biochemicals









MedKoo product information:




Description of AZD7451: AZD7451 is a tropomyosin receptor kinase (TRK) inhibitor with potential antineoplastic activity. AZD7451 binds to TRK, thereby preventing the neurotrophin-TRK interaction and subsequent TRK activation. This may eventually result in an inhibition of tumor cell proliferation in TRK-expressing tumor cells. TRK, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth, invasion and survival. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).


Current developer: AstraZenca.


MedKoo Cat#: 205820

Name:  AZD7451



Synonym:  AZD7451; AZD-7451; AZD 7451


IUPAC/Chemical name: 



Chemical structure

Theoretical analysis








Availability and price:


This agent is not in stock, which may be available through  custom synthesis.



To inquire quotation and lead time or to ask questions, please send email to to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.



Highlights of recent research using this agent








Contact MedKoo:

Tel: 919-636-5577
Fax: 919-980-4831


(Keyword; CAS#; MedKoo Cat#)








About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

MedKoo Biosciences. All Rights Reserved